Saturday 17 October 2026 Export GH’s income statement to Excel — free account

Guardant Health, Inc.

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 44.3%, EPS fell 12.5%, free cash flow fell 5.46% and total debt rose 34.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

158.29 7.59 −4.58%

Follow GH

Alert me

Market cap: $22.3B
P/E: 0.0×
Fwd P/E: −43.3×
Dividend yield: —
F-score: 5/9
Altman Z: 2.02
Beneish M: −2.78
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.08

Total sells 173.91

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	—	—	—
Sell	3	11	2	—	4	2	9	11	1	6	5	1

Insider Ownership 3.09%

Capital & Financial Ratios $m

Market Cap 22,260.00

Revenue 1,183.10

Net Income (453.44)

Free Cash Flow (240.72)

Net Debt 449.47

Current Ratio 4.03

Debt/Equity (6.74)

P/E ratio 0.00

Fwd P/E (43.30)

P/S ratio 17.78

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 1.95%

Next Y EPS Growth 34.56%

Next Y revenue growth 38.29%

Next 5Y EPS Growth 60.22%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 58.69%

10-year low 10-year high

EV/Sales against its own 10 years 59.19%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,169	840	1,202	1,053
Receivables	89	110	138	144
Inventory	62	71	86	105
Other	—	—	—	—
	1,347	1,055	1,466	1,365

	2023	2024	2025	Q'26
Payables	52	39	54	94
ST’ Debt	—	—	—	—
Other	—	—	—	—
	206	226	303	339

Compound Annual Growth %

	10y	5y	3y
Sales	—	27.92%	29.75%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	302	335	—	—	—
’25	203	232	265	281	982
’24	168	177	191	202	739
’23	129	137	143	155	564
’22	96	109	117	127	450
’21	79	92	95	108	374
’20	68	66	75	78	287

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(66)	(58)	—	—	—
’25	(63)	(60)	(35)	(26)	(185)
’24	(30)	(94)	(51)	(65)	(240)
’23	(74)	(94)	(78)	(79)	(325)
’22	(29)	(112)	(78)	(91)	(309)
’21	(16)	(63)	(53)	(77)	(209)
’20	(13)	(23)	(8)	(59)	(104)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(71)	(70)	—	—	—
’25	(67)	(66)	(46)	(54)	(233)
’24	(37)	(99)	(55)	(83)	(275)
’23	(82)	(101)	(80)	(83)	(345)
’22	(51)	(135)	(100)	(101)	(387)
’21	(26)	(81)	(75)	(102)	(284)
’20	(41)	(33)	(18)	(67)	(158)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.85)	(0.90)	—	—	—
’25	(0.77)	(0.80)	(0.74)	(1.00)	(3.32)
’24	(0.94)	(0.84)	(0.88)	(0.90)	(3.56)
’23	(1.30)	(0.67)	(0.73)	(1.58)	(4.28)
’22	(1.21)	(2.25)	(1.58)	(1.36)	(6.41)
’21	(1.09)	(0.96)	(1.06)	(0.89)	(4.00)
’20	(0.29)	(0.57)	(0.78)	(0.94)	(2.60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	27.04	33.70	55.90	85.41	24.63	20.67	15.81	30.97	Analyst estimates 2026–2028 Powerpack
	High	—	—	49.55	112.22	138.65	181.07	102.85	41.06	38.53	112.43
People
People	Employees	—	348	454	622	864	1,373	1,793	1,779	2,021	2,506
	Revenue/emp, $m	0.00	0.14	0.20	0.34	0.33	0.27	0.25	0.32	0.37	0.39
Income, $m
Income, $m	Revenue	25	50	91	214	287	374	450	564	739	982
	Gross margin, %	12.38	36.56	52.33	67.01	67.73	67.11	65.23	59.74	60.79	64.46
	EBT	(46)	(83)	(84)	(70)	(246)	(384)	(653)	(479)	(435)	(418)
	EBT margin, %	(182.71)	(166.96)	(92.92)	(32.52)	(85.76)	(102.89)	(145.36)	(84.90)	(58.87)	(42.52)
	Net income	(46)	(83)	(84)	(68)	(246)	(385)	(655)	(479)	(436)	(416)
	Depreciation	4	6	7	9	25	38	43	29	36	34
Per share, $
Per share, $	Revenue	1.93	3.96	2.98	2.37	2.94	3.69	4.40	5.04	6.02	7.83
	Earnings	(3.53)	(6.61)	(2.80)	(0.84)	(2.60)	(4.00)	(6.41)	(4.28)	(3.56)	(3.32)
	Cash flow	(2.81)	(5.74)	(2.37)	(0.52)	(1.07)	(2.06)	(3.03)	(2.90)	(1.95)	(1.47)
	Capex	(0.14)	(0.53)	(0.66)	(0.23)	(0.55)	(0.74)	(0.76)	(0.18)	(0.29)	(0.39)
	Free cash flow	(2.95)	(6.27)	(3.04)	(0.75)	(1.62)	(2.80)	(3.79)	(3.08)	(2.24)	(1.86)
	Book value	0.00	24.53	15.89	8.81	13.32	6.37	0.59	1.42	(1.14)	(0.79)
	Shares, m	13	13	30	91	98	101	102	112	123	125
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	5.88	5.88	12.61	33.02	43.83	27.12	6.14	5.26	5.07	13.04
	P/B	0.00	0.00	2.37	8.87	9.68	15.71	45.84	18.71	0.00	0.00
	EV/Sales	1.94	1.94	7.99	30.77	40.38	27.66	6.42	5.21	5.48	13.35
	EV/FCF	(1.60)	(1.60)	(7.84)	(100.17)	(73.28)	(34.23)	(7.13)	(8.09)	(13.84)	(52.23)
Cash, $m
Cash, $m	Operating cash flow	(37)	(72)	(72)	(47)	(104)	(209)	(309)	(325)	(240)	(185)
	Capex	(2)	(7)	(20)	(21)	(54)	(75)	(77)	(20)	(35)	(48)
	Free cash flow	(38)	(79)	(92)	(68)	(158)	(284)	(387)	(345)	(275)	(233)
Balance, $m
Balance, $m	Working capital	89	223	422	525	1,822	919	998	1,141	830	1,163
	Total debt	17	0	7	40	806	1,135	1,137	1,140	1,143	1,504
	Net debt	(78)	(221)	(412)	(483)	(989)	202	126	(29)	303	302
	Shareholders’ equity	—	309	483	798	1,298	645	60	159	(140)	(99)
Returns, %
Returns, %	ROA	(26.90)	(51.90)	(18.29)	(9.76)	(15.69)	(18.13)	(34.32)	(28.23)	(26.67)	(23.79)
	ROIC	0.00	(54.57)	(81.60)	(16.31)	(51.42)	(30.32)	(182.59)	(271.47)	(170.17)	(134.56)
	ROE	31.71	61.09	(58.31)	(11.81)	(24.21)	(41.75)	(185.65)	(438.13)	(4,584.50)	348.42

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ILMN Illumina, Inc.	$40.5B	48.4×	34.7×	+9.44% (above 0%: growing)	−8.05% (below 0%: shrinking)	−18.27% (below 0%: shrinking)	66.44%	21.14%	Compare
MTD Mettler-Toledo International, Inc.	$32.8B	36.4×	25.5×	+4.48% (above 0%: growing)	+18.30% (above 0%: growing)	+33.01% (above 0%: growing)	63.29%	30.61%	Compare
DGX Quest Diagnostics Incorporated	$26.4B	24.6×	20.8×	+10.21% (above 0%: growing)	+14.74% (above 0%: growing)	+5.28% (above 0%: growing)	33.75%	15.08%	Compare
LH Labcorp Holdings Inc.	$26.4B	26.2×	19.0×	+5.78% (above 0%: growing)	+28.42% (above 0%: growing)	−42.01% (below 0%: shrinking)	29.80%	12.10%	Compare
GH Guardant Health, Inc.	$22.3B	— (loss-making)	— (loss-making)	+44.33% (above 0%: growing)	n/m	−5.46% (below 0%: shrinking)	65.39%	(38.55%)
MEDP Medpace Holdings, Inc.	$17.6B	35.6×	26.7×	+17.24% (above 0%: growing)	+36.39% (above 0%: growing)	−3.03% (below 0%: shrinking)	71.36%	20.76%	Compare
RVTY Revvity Inc.	$17.3B	72.7×	37.5×	+1.31% (above 0%: growing)	+2.17% (above 0%: growing)	+59.29% (above 0%: growing)	57.13%	12.24%	Compare
CRL Charles River Laboratories International, Inc.	$14.6B	— (loss-making)	29.6×	−2.72% (below 0%: shrinking)	n/m	−12.22% (below 0%: shrinking)	36.19%	11.94%	Compare
ICLR ICON PLC	$13.5B	254×	23.8×	+1.20% (above 0%: growing)	−59.31% (below 0%: shrinking)	+109.66% (above 0%: growing)	23.23%	6.68%	Compare
Median of peers	$22.0B	36.4×	26.1×	+5.13%	+14.74%	+1.13%	46.66%	13.66%

All 52 Diagnostics & Research stocks →